Repetitive TMS of the Posterior DMN in AD

Korábbi kezelés

• Metal implants in the head (except dental), pacemaker, cochlear implants, or any other non-removable items that are contraindications to MR imaging.
• Treatment currently or within 3 months before Baseline with any of the following medications:
  • Typical and atypical antipsychotics (i.e. Clozapine, Olanzapine)
  • Antiepileptics drugs (i.e. Carbamazepine, Primidone, Pregabalin, Gabapentin)
  • Memantine

Más betegség

• Significant neurodegenerative disorder of the central nervous system other than Alzheimer's disease
• History of seizure (with the exception of febrile seizures in childhood)
• Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition - Text Revision (DSM IV-TR) criteria met for any of the following within specified period:
  • Major depressive disorder (current)
  • Schizophrenia (lifetime)
  • Other psychotic disorders, bipolar disorder, or substance (including alcohol) related disorders (within the past 5 years)

Egyéb

• Significant intracranial focal or vascular pathology seen on brain MRI scan

• The patient and the responsible caregiver have signed the Informed Consent Form.
• The patient has probable AD, diagnosed according to NINCDS-ADRDA criteria.
• The patient is a man or woman, aged ≤ 85 years.
• The patient has a CDR total score of 0.5 or 1 (mild to moderate) and MMSE score of 18-26 (inclusive) at Screening.
• Has at least one identified adult caregiver
• The patient has been treated with acetylcholinesterase inhibitor (AChEI), i.e., donepezil, galantamine, or rivastigmine, at the time of Screening
  • for at least 3 months
  • The current dosage regimen must have remained stable for ≥ 8 weeks
  • It must be planned that the dosage regimen will remain stable throughout participation in the study
• The patient is able to comply with the study procedures in the view of the investigator.